SG11201407732SA - Lentiviral vectors containing an mhc class i promoter - Google Patents

Lentiviral vectors containing an mhc class i promoter

Info

Publication number
SG11201407732SA
SG11201407732SA SG11201407732SA SG11201407732SA SG11201407732SA SG 11201407732S A SG11201407732S A SG 11201407732SA SG 11201407732S A SG11201407732S A SG 11201407732SA SG 11201407732S A SG11201407732S A SG 11201407732SA SG 11201407732S A SG11201407732S A SG 11201407732SA
Authority
SG
Singapore
Prior art keywords
international
rule
promoter
applicant
mhc class
Prior art date
Application number
SG11201407732SA
Inventor
Emeline Sarry
Cécile Bauche
Original Assignee
Theravectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravectys filed Critical Theravectys
Publication of SG11201407732SA publication Critical patent/SG11201407732SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/174630 A1 (51) International Patent Classification: A61K39/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/059041 30 April 2013 (30.04.2013) English English (30) Priority Data: 12305566.7 23 May 2012 (23.05.2012) EP (71) Applicant: THERAVECTYS [FR/FR]; 1, Mail du Profes- seur Georges Mathe, F-94800 Villejuif (FR). (72) Inventors: SARRY, Emeline; 68, avenue Augustin Du- mont, F-92240 Malakoff (FR). BAUCHE, Cecile; 104, av­ enue de Choisy, F-75013 Paris (FR). (74) Agent: LAU, Sarah; Kilburn & Strode LLP, 20 Red Lion Street, London Greater London WC14PJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, — BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) © •t i> i-H o CJ (54) Title: LENTIVIRAL VECTORS CONTAINING AN MHC CLASS PROMOTER I (57) Abstract: The present invention relates to the insertion of a promoter sequence from an MHC class I gene promoter into a len- tiviral vector in order to direct the transcription of transgene, which preferably encodes an a immunogenic polypeptide to be ex­ pressed in a mammalian cell host, preferably APC (DCs). The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
SG11201407732SA 2012-05-23 2013-04-30 Lentiviral vectors containing an mhc class i promoter SG11201407732SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305566.7A EP2666477A1 (en) 2012-05-23 2012-05-23 Lentiviral vectors containing an MHC class I promoter
PCT/EP2013/059041 WO2013174630A1 (en) 2012-05-23 2013-04-30 Lentiviral vectors containing an mhc class i promoter

Publications (1)

Publication Number Publication Date
SG11201407732SA true SG11201407732SA (en) 2014-12-30

Family

ID=48289150

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407732SA SG11201407732SA (en) 2012-05-23 2013-04-30 Lentiviral vectors containing an mhc class i promoter

Country Status (18)

Country Link
US (1) US8951535B2 (en)
EP (2) EP2666477A1 (en)
JP (1) JP5938143B2 (en)
KR (1) KR101774929B1 (en)
CN (1) CN104736167B (en)
AU (1) AU2013265586B2 (en)
BR (1) BR112014028944B1 (en)
CA (1) CA2873473C (en)
ES (1) ES2498277T3 (en)
HK (1) HK1211837A1 (en)
IL (1) IL235705A (en)
IN (1) IN2014DN10123A (en)
NZ (1) NZ702345A (en)
PL (1) PL2678032T3 (en)
PT (1) PT2678032E (en)
SG (1) SG11201407732SA (en)
WO (1) WO2013174630A1 (en)
ZA (1) ZA201408652B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520316A (en) * 2013-06-03 2016-07-14 テラベクティ Lentiviral vector containing MHC class I, MHC class II or β2 microglobulin upstream promoter sequence
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
KR20220005208A (en) 2020-07-06 2022-01-13 주식회사 지씨셀 A Novel Cell for Transplantation with Reduced Immunogenicity
CN114107393A (en) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 Lentiviral vector and lentiviral particle for treating hepatitis B as well as preparation methods and applications of lentiviral vector and lentiviral particle
KR20240073177A (en) * 2022-11-10 2024-05-24 전남대학교산학협력단 Pharmaceutical composition for preventing or treating glioma comprising multiple epitope peptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19720152A1 (en) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Retroviral vector system for gene therapy
FR2777909B1 (en) 1998-04-24 2002-08-02 Pasteur Institut USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
DK1092779T3 (en) * 1999-10-11 2010-02-15 Pasteur Institut Lentivirus virus vectors for the preparation of immunotherapeutic preparations
ATE531808T1 (en) 1999-10-12 2011-11-15 Pasteur Institut LENTIVIRAL TRIPLEX DNA AND VECTORS AND RECOMBINANT CELLS WITH LENTIVIRAL TRIPLEX DNA
FR2870126B1 (en) 2004-05-17 2009-07-17 Pasteur Institut RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
BRPI0813194B8 (en) 2007-08-03 2021-05-25 Centre Nat Rech Scient kit, lentiviral vector particles, composition of plasmid vectors, chimeric hiv-1 derived antigen, vsv-g envelope protein, nucleic acid molecules, immunogenic composition and use of a lentiviral vector

Also Published As

Publication number Publication date
IL235705A0 (en) 2015-01-29
IN2014DN10123A (en) 2015-08-21
JP5938143B2 (en) 2016-06-22
US8951535B2 (en) 2015-02-10
PT2678032E (en) 2014-09-09
KR20150014472A (en) 2015-02-06
AU2013265586A1 (en) 2014-12-11
KR101774929B1 (en) 2017-09-19
WO2013174630A1 (en) 2013-11-28
JP2015518716A (en) 2015-07-06
CA2873473A1 (en) 2013-11-28
EP2678032B1 (en) 2014-06-18
CN104736167A (en) 2015-06-24
CA2873473C (en) 2019-05-07
HK1211837A1 (en) 2016-06-03
IL235705A (en) 2016-10-31
BR112014028944B1 (en) 2020-11-10
ES2498277T3 (en) 2014-09-24
EP2666477A1 (en) 2013-11-27
PL2678032T3 (en) 2014-11-28
AU2013265586B2 (en) 2015-09-03
EP2678032A1 (en) 2014-01-01
NZ702345A (en) 2016-03-31
ZA201408652B (en) 2016-09-28
US20140120132A1 (en) 2014-05-01
CN104736167B (en) 2018-07-27
BR112014028944A2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
SG11201807188VA (en) Modified cells for immunotherapy
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201807912SA (en) Vaccine against rsv
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201408261UA (en) Syringe
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201806398YA (en) Optimized factor viii genes
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201806542PA (en) Anti-mica antibodies
SG11201803169WA (en) Cellulase variants and polynucleotides encoding same
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201408746XA (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201808710UA (en) Novel immunogenic cd1d binding peptides